
With a mifepristone safety review due by March and Senate control shifting in January, the FDA faces an extended stretch without a permanent leader.
Verquvo is a soluble guanylate cyclase stimulator indicated to reduce the risk of cardiovascular death and heart failure.
Medication Pearl of the Day: Vericiguat (Verquvo)
Vericiguat is a soluble guanylate cyclase (sGC) stimulator indicated to reduce the risk of cardiovascular death and heart failure (HF) emergency department visits following an initial hospitalization for HF or need for outpatient intravenous diuretics in adults with symptomatic chronic HF and ejection fraction less than 45%.
Insight:
Sources:





